MBX Biosciences (MBX) and The Competition Head to Head Survey

MBX Biosciences (NYSE:MBX) is one of 451 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare MBX Biosciences to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for MBX Biosciences and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	0	0	8	0	3.00
MBX Biosciences Competitors	4777	9993	16020	364	2.38

MBX Biosciences presently has a consensus price target of $37.6250, suggesting a potential upside of 190.54%. As a group, “Pharmaceutical preparations” companies have a potential upside of 140.22%. Given MBX Biosciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe MBX Biosciences is more favorable than its competitors.

Valuation & Earnings

This table compares MBX Biosciences and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-2.85
MBX Biosciences Competitors	$443.97 million	-$69.05 million	-8.82

MBX Biosciences’ competitors have higher revenue, but lower earnings than MBX Biosciences. MBX Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares MBX Biosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	N/A	N/A
MBX Biosciences Competitors	-2,615.58%	-412.87%	-44.60%

Insider and Institutional Ownership

38.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MBX Biosciences beats its competitors on 8 of the 11 factors compared.

MBX Biosciences Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.